Advertisement Pharmaceutical Business review - Page 151 of 5270 -
Pharmaceutical Business review is using cookies

ContinueLearn More
Close
April 28, 2026

BioMarin acquires Amicus Therapeutics for $4.8bn

BioMarin Pharmaceutical has completed its acquisition of Amicus Therapeutics, buying the company for $14.50 per share in an all-cash deal for a total equity value of nearly $4.8bn.

BioMarin secures US rights to DMX-200, an oral investigational small molecule for FSGS. Credit: Michael Vi / Shutterstock.com.